# Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial

> **NCT05468892** · PHASE2 · COMPLETED · sponsor: **University of Campania Luigi Vanvitelli** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Colon Cancer

## Interventions

- **DRUG:** Trifluridine Tipiracil
- **DRUG:** Panitumumab 20 MG/1 ML Intravenous Solution [VECTIBIX]

## Key facts

- **NCT ID:** NCT05468892
- **Lead sponsor:** University of Campania Luigi Vanvitelli
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-29
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-06-30
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468892, "Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05468892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*